Reply to: "Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: What are the optimal criteria?"

J Hepatol. 2024 Apr;80(4):e172-e173. doi: 10.1016/j.jhep.2023.12.017. Epub 2023 Dec 26.

Authors

Joshua S Norman¹, Neil Mehta²

Affiliations

¹ Department of Internal Medicine, Stanford, CA, USA.
² Division of Gastroenterology and Hepatology, University of California, San Francisco, USA. Electronic address: neil.mehta@ucsf.edu.

PMID: 38154740
DOI: 10.1016/j.jhep.2023.12.017

No abstract available

Publication types

Letter

MeSH terms

Biomarkers
Biomarkers, Tumor
Carcinoma, Hepatocellular* / pathology
Carcinoma, Hepatocellular* / surgery
Humans
Liver Neoplasms* / pathology
Liver Neoplasms* / surgery
Liver Transplantation*
Patient Selection
Prothrombin
alpha-Fetoproteins

Substances

alpha-Fetoproteins
Biomarkers, Tumor
Biomarkers
Prothrombin